Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bas J M Peters

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Pharmacogenomics|August 18, 2010
Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarctionBas J M Peters, Andrei S Rodin, Olaf H Klungel, et al.
Pharmacogenetics and Genomics|May 6, 2009
The effect of nine common polymorphisms in coagulation factor genes (F2, F5, F7, F12 and F13 ) on the effectiveness of statins: the GenHAT studyAnke-Hilse Maitland-van der Zee, Bas J M Peters, Amy I Lynch, et al.
Lung|November 16, 2023
Methotrexate Polyglutamate Concentrations as a Possible Predictive Marker for Effectiveness of Methotrexate Therapy in Patients with Sarcoidosis: A Pilot StudyMontse Janssen Bonás, Janani Sundaresan, Ruth G M Keijsers, et al.
Scientific Reports|March 19, 2021
Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the NetherlandsChristine M Cramer-van der Welle, Marjon V Verschueren, Merel Tonn, et al.
Pharmacoepidemiology and Drug Safety|December 9, 2020
Systematic evaluation of the efficacy-effectiveness gap of systemic treatments in extensive disease small cell lung cancerChristine M Cramer-van der Welle, Franz M N H Schramel, Bas J M Peters, et al.
Pharmacogenetics and Genomics|November 23, 2013
The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam StudyCatherine E de Keyser, Bas J M Peters, Matthijs L Becker, et al.
Atherosclerosis|July 12, 2011
Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MIBas J M Peters, Helmi Pett, Olaf H Klungel, et al.
Clinical Lung Cancer|August 6, 2025
Real World Effectiveness of Durvalumab in Stage III Unresectable Non-small Cell Lung Cancer: What is the Role of PD-L1 Expression?Hanieh Abedian Kalkhoran, Marjon V Verschueren, Bas J M Peters, et al.
Pharmacogenetics and Genomics|June 14, 2008
Effectiveness of statins in the reduction of the risk of myocardial infarction is modified by the GNB3 C825T variantBas J M Peters, Anke-Hilse Maitland-van der Zee, Bruno H Ch Stricker, et al.
Clinical Lung Cancer|April 22, 2025
The Toxicity Profile of Pemetrexed in Non-Small Cell Lung Cancer Patients With Moderate Renal Impairment: A Retrospective Cohort StudyMart P Kicken, Rob Ter Heine, Intissar Azarfane, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Pharmacogenomics|August 18, 2010
Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarctionBas J M Peters, Andrei S Rodin, Olaf H Klungel, et al.
Pharmacogenetics and Genomics|May 6, 2009
The effect of nine common polymorphisms in coagulation factor genes (F2, F5, F7, F12 and F13 ) on the effectiveness of statins: the GenHAT studyAnke-Hilse Maitland-van der Zee, Bas J M Peters, Amy I Lynch, et al.
Lung|November 16, 2023
Methotrexate Polyglutamate Concentrations as a Possible Predictive Marker for Effectiveness of Methotrexate Therapy in Patients with Sarcoidosis: A Pilot StudyMontse Janssen Bonás, Janani Sundaresan, Ruth G M Keijsers, et al.
Scientific Reports|March 19, 2021
Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the NetherlandsChristine M Cramer-van der Welle, Marjon V Verschueren, Merel Tonn, et al.
Pharmacoepidemiology and Drug Safety|December 9, 2020
Systematic evaluation of the efficacy-effectiveness gap of systemic treatments in extensive disease small cell lung cancerChristine M Cramer-van der Welle, Franz M N H Schramel, Bas J M Peters, et al.
Pharmacogenetics and Genomics|November 23, 2013
The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam StudyCatherine E de Keyser, Bas J M Peters, Matthijs L Becker, et al.
Atherosclerosis|July 12, 2011
Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MIBas J M Peters, Helmi Pett, Olaf H Klungel, et al.
Clinical Lung Cancer|August 6, 2025
Real World Effectiveness of Durvalumab in Stage III Unresectable Non-small Cell Lung Cancer: What is the Role of PD-L1 Expression?Hanieh Abedian Kalkhoran, Marjon V Verschueren, Bas J M Peters, et al.
Pharmacogenetics and Genomics|June 14, 2008
Effectiveness of statins in the reduction of the risk of myocardial infarction is modified by the GNB3 C825T variantBas J M Peters, Anke-Hilse Maitland-van der Zee, Bruno H Ch Stricker, et al.
Clinical Lung Cancer|April 22, 2025
The Toxicity Profile of Pemetrexed in Non-Small Cell Lung Cancer Patients With Moderate Renal Impairment: A Retrospective Cohort StudyMart P Kicken, Rob Ter Heine, Intissar Azarfane, et al.
Pageof 4